+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Genovis AB (GENO) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 55 Pages
  • September 2024
  • GlobalData
  • ID: 2607235
Genovis AB (GENO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the analyst to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Genovis AB (Genovis) develops, produces, and markets enzyme products, which facilitate the development and quality control of biological drugs. Genovis offers an array of products, including 25 enzymes in different product formats under the SmartEnzymes brand, and technologies related to antibody labeling and remodeling of antibody glycans. Its SmartEnzymes product portfolio encompasses Fabricator (IdeS), Gingiskhan (KGP), Fabulous (SpeB), Glycinator (EndoS49), Fabricator Z (IdeZ), Gingisrex (Rgp) and IgGzero (EndoS). The company’s products are used for antibody molecules analysis to identify and characterize proteins, antibody-based biotherapeutics; monoclonal antibodies, antibody drug conjugates and biosimilars. The company has an operational presence in Europe, North America, and Asia. Genovis is headquartered in Kavlinge, Sweden.

Genovis AB Key Recent Developments

  • Sep 23, 2024: Genovis Launches FabRICATOR Xtra: Next-Generation Enzyme for Future Antibody Therapeutics
  • May 15, 2024: Genovis Announces Interim Report January - March 2024
  • Apr 24, 2024: Genovis Annual Report 2023 Published
  • Feb 15, 2024: Genovis : Year-end report January-December 2023

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Genovis AB - Key Facts
  • Genovis AB - Key Employees
  • Genovis AB - Key Employee Biographies
  • Genovis AB - Major Products and Services
  • Genovis AB - History
  • Genovis AB - Company Statement
  • Genovis AB - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Genovis AB - Business Description
  • Product Category: Antibodies
  • Performance
  • Product Category: Enzyme
  • Performance
  • Geographical Segment: Other Countries
  • Performance
  • Geographical Segment: Sweden
  • Performance
  • R&D Overview
  • Genovis AB - Corporate Strategy
  • Genovis AB - SWOT Analysis
  • SWOT Analysis - Overview
  • Genovis AB - Strengths
  • Genovis AB - Weaknesses
  • Genovis AB - Opportunities
  • Genovis AB - Threats
  • Genovis AB - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Genovis AB, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Genovis AB, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Genovis AB, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Sep 23, 2024: Genovis Launches FabRICATOR Xtra: Next-Generation Enzyme for Future Antibody Therapeutics
  • May 15, 2024: Genovis Announces Interim Report January - March 2024
  • Apr 24, 2024: Genovis Annual Report 2023 Published
  • Feb 15, 2024: Genovis : Year-end report January-December 2023
  • Aug 24, 2023: Genovis : Half-Yearly Report January-June 2023
  • Jun 02, 2023: Genovis Launch Innovative Igm-Specific Protease With Wide-Ranging Applications in Life Science Markets
  • May 16, 2023: Genovis announces interim report January-March 2023
  • May 16, 2023: Genovis Announces Annual General Meeting May 16, 2023
  • Apr 25, 2023: Genovis announces annual results 2022
  • Apr 11, 2023: Genovis Notice Convening the 2023 Annual General Meeting
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Genovis AB, Key Facts
  • Genovis AB, Key Employees
  • Genovis AB, Key Employee Biographies
  • Genovis AB, Major Products and Services
  • Genovis AB, History
  • Genovis AB, Subsidiaries
  • Genovis AB, Key Competitors
  • Genovis AB, Ratios based on current share price
  • Genovis AB, Annual Ratios
  • Genovis AB, Interim Ratios
  • Genovis AB, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Genovis AB, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
  • Genovis AB, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Genovis AB, Performance Chart (2019 - 2023)
  • Genovis AB, Ratio Charts
  • Genovis AB, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
  • Genovis AB, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Samples

Loading
LOADING...

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Thermo Fisher Scientific Inc
  • Abcam Ltd
  • Santa Cruz Biotechnology Inc
  • Bio-Rad Laboratories Inc
  • Global Life Sciences Solutions USA LLC
  • New England Biolabs Inc
  • Agilent Technologies Inc